Seeking Alpha

OncoGenex gets a lift from Needham

  • OncoGenex Pharmaceuticals (OGXI) jumps 10% before the bell.
  • Needham's Chad Messer says that "while Xtandi and other prostate cancer agents in development may eventually erode chemotherapy use in prostate cancer, this concern is nothing new and [may not] have a material effect on the long-term value" of the shares.
  • OGXI upgraded to Strong Buy. Price target lifted to $30 (from $20) — so Messer is essentially looking for the shares to quadruple.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: